Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Ivermectin for COVID-19: real-time meta analysis of 95 studies (ivmmeta)
Covid Analysis (Preprint) (meta analysis)
Covid Analysis, Ivermectin for COVID-19: real-time meta analysis of 95 studies (ivmmeta), (Preprint) (meta analysis)
Feb 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
• Statistically significant improvements are seen for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance. All remain significant after exclusions. 59 studies from 53 independent teams in 23 different countries show statistically significant improvements in isolation (41 primary outcome, 39 most serious outcome).
• Meta analysis using the most serious outcome shows 62% [51‑70%] and 82% [73‑88%] improvement for early treatment and prophylaxis, with similar results after exclusion based sensitivity analysis, for primary outcomes, for peer-reviewed studies, and for RCTs.
• Results are very robust — in worst case exclusion sensitivity analysis 60 of 95 studies must be excluded to avoid finding statistically significant efficacy.
• No treatment, vaccine, or intervention is 100% effective and available. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, which may be significantly more effective. Only 22% of ivermectin studies show zero events with treatment.
• Over 20 countries adopted ivermectin for COVID-19. The evidence base is much larger and has much lower conflict of interest than typically used to approve drugs.
• All data to reproduce this paper and sources are in the appendix. See [Bryant, Hariyanto, Kory, Lawrie, Nardelli] for other meta analyses with similar results confirming efficacy.
Percentage improvement with ivermectin (more)
All studiesEarly treatmentProphylaxisStudies Patients Authors
All studies62% [54‑69%]****62% [51‑70%]****82% [73‑88%]**** 95134,554 1,023
Randomized Controlled TrialsRCTs54% [39‑65%]****57% [41‑69%]****79% [50‑91%]*** 4511,643 621
Mortality51% [37‑62%]****40% [12‑59%]**90% [50‑98%]** 48120,338 549
HospitalizationHosp.34% [20‑45%]****53% [27‑69%]***67% [54‑77%]**** 2944,784 405
Cases78% [67‑85%]****-78% [67‑85%]**** 1613,696 140
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit